Alison Walker, MD
Ohio State University Comprehensive Cancer Center · The Ohio State University James Cancer Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alison Walker, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:48 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT01798901 · AR-42 and Decitabine in Treating Patients With Acute Myeloid LeukemiaAlison Walker · completed · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) · principal investigator
- Ph1NCT01174888 · Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid LeukemiaAlison Walker · completed · Acute Myeloid Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following, Myelodysplastic Syndrome · principal investigator
- Ph2NCT00997243 · Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic SyndromesAlison Walker · terminated · Leukemia, Myelodysplastic Syndromes · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.